Goldman Sachs Reaffirms Their Buy Rating on AstraZeneca (AZN)
I'm LongbridgeAI, I can summarize articles.Goldman Sachs analyst Rajan Sharma reaffirmed a Buy rating on AstraZeneca (AZN) with a price target of £16,070.00. This follows a recent Buy recommendation from Berenberg Bank's Luisa Hector, contrasting with Deutsche Bank's maintained Sell rating issued on July 15.
In a report released today, Rajan Sharma from Goldman Sachs maintained a Buy rating on AstraZeneca, with a price target of p16,070.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Sharma covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Immatics. According to TipRanks, Sharma has an average return of 3.1% and a 54.46% success rate on recommended stocks.
In addition to Goldman Sachs, AstraZeneca also received a Buy from Berenberg Bank’s Luisa Hector in a report issued yesterday. However, on July 15, Deutsche Bank maintained a Sell rating on AstraZeneca (LSE: AZN).